Form 8-K Amendment No. 1

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 8-K/A

(Amendment No. 1)

 


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 19, 2007

Date of Report (Date of earliest event reported)

 


NPS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware   0-23272   87-0439579

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification Number)

550 Hills Drive, 3rd Floor

Bedminster, New Jersey 07921

(Address of principal executive offices)

(908) 450-5300

(Registrant’s telephone number, including area code)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Explanatory Note

NPS Pharmaceuticals is filing this Amendment No. 1 to its Current Report on Form 8-K filed on July 19, 2007 to report the effective date for the previously reported resignation of a named executive officer.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On October 10, 2007, Mr. Val R. Antczak announced that he will resign as Senior Vice President, Legal Affairs, General Counsel and Corporate Secretary of the company as of November 15, 2007. Mr. Andrew Rackear will succeed him as of November 15, 2007, as the Senior Vice President, Legal Affairs, General Counsel and Corporate Secretary of the company.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 16, 2007   NPS PHARMACEUTICALS, INC.
  By:  

/s/ VAL R. ANTCZAK

   

Val R. Antczak, Senior Vice President

Legal Affairs and General Counsel